SCHEMBL19970764

SCHEMBL19970764

O=C(OCc1ccccc1)N1CCN(Cc2ccc3nc(-c4cccnc4)[nH]c3c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.47
CDK1 P06493 3/20 0.47
CCNB1 P14635 3/20 0.47
CDK2 P24941 3/20 0.47
AURKB Q96GD4 3/20 0.47
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
SLC2A1 P11166 1/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KIT P10721 3/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
RECQL P46063 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GRIN2B Q13224 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CHEK2 O96017 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970763 0.93 KIT (0.45) ALDH1A1HPGDKITGRIN2BMEN1
SCHEMBL19970835 0.92 BCHE (0.53) AURKACDK1CCNB1CDK2AURKB
SCHEMBL19970809 0.87 ACACB (0.52) BCHEACHEALDH1A1HPGDHSD17B10
SCHEMBL19970834 0.85 GRIN2B (0.49) BCHEACHETP53GRIN2BMEN1
SCHEMBL19970771 0.84 CBFB (0.53) AURKACDK1CCNB1CDK2AURKB
SCHEMBL19986753 0.84 SLC2A1 (0.54) BCHEACHESLC2A1MEN1KMT2A
SCHEMBL19970777 0.84 SLC2A1 (0.58) BCHEACHESLC2A1CHEK2HDAC6
SCHEMBL19970808 0.82 ENPP2 (0.51) ALDH1A1HPGDGRIN2BCYP3A4CYP2D6
SCHEMBL19970755 0.79 GRIN2B (0.47) AURKACDK1CCNB1CDK2AURKB
SCHEMBL19970817 0.78 CYP3A4 (0.52) AURKACDK1CCNB1CDK2AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS AURKA 2228/4885CDK1 2779/4885CCNB1 4229/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS AURKA 2228/4885CDK1 2779/4885CCNB1 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.